Venture capital firm

Boehringer Ingelheim Venture Fund

Strategic venture fund of Boehringer Ingelheim investing worldwide in pioneering science for patients

Write a review

Digital
Science
Series A
Healthtech
+2 more

Visit Website Get introducedRequest an introduction Write a Review

Own this listing? Claim it

TrustList summary

This is the corporate venture arm of the Boehringer Ingelheim Corporation, set up to back outside science for the parent group. The fund began investing in 2010 and works internationally.

What Boehringer Ingelheim Venture Fund does

Science investment: backing for pioneering research with the potential to help patients.
Worldwide reach: the fund invests across regions, on the view that innovation is not limited by geography.
Portfolio: its site has a section on investment focus and portfolio companies.

Customers and markets

Science-led companies whose work could bring a significant benefit to patients, wherever they are located.

The fund describes its aim as supporting research that may give real benefit to patients, and its site sets out its investment focus and the companies it holds.

Key facts

Parent: Boehringer Ingelheim Corporation
Investing since: 2010
Geography: worldwide

Summary written by TrustList from the business's own published information, Oct 2026.

Gallery

2 images - click to enlarge

Categories & features

Rankings

Boehringer Ingelheim Venture Fund is ranked on 3 TrustList rankings: #26 on 1, #38 on 1 and #49 on 1.

Every ranking orders its listings by their reviews, how complete the profile is and the Trust Score. Boehringer Ingelheim Venture Fund has no reviews yet and 3 of the 10 profile details we look for. Where no listing on a page has been reviewed, the order follows the profiles alone.

Venture capital firm · 3 rankings

#26of 69
Hong kong
It is one of 4 here listing series a and one of 5 here listing science.
Of the top 59 here, 10 also cover partners and 7 also cover banking; 25 also work in New York City and 24 also work in London.
Behind Black Pearl Capital Partners, ahead of BofA Securities.
#38of 110
Boston
It is one of 9 here listing healthtech.
Of the top 69 here, 11 also cover biotech and 10 also cover seed stage; 19 also work in San Francisco and 17 also work in Silicon Valley.
Behind Blue Ivy Ventures, ahead of Bold Capital Partners.
#49of 147
Healthtech investors
It is one of 7 here listing science and one of 9 here listing series a.
Of the top 64 here, 13 also cover growth stage and 10 also cover artificial intelligence; 7 also work in Boston and 7 also work in Chicago.
Behind Bluegrass Angels, ahead of Borealis Ventures.